Interim Reports
Latest Reports
-
Interim Report 2 2022/23
The online sales and lead generation strategy continues to deliver. As a result, sales from August to October this year reached 2.7 KSEK — an increase of 50 % compared to any previous corresponding period.
-
Interim Report 1 2022/23
Despite a summer-sluggish period ending in July, sales were just one unit away from surpassing our best quarter ever; the same period last year.
-
Year-end Report 2021/22
Sales more than doubled in 2021/22, compared to previous financial year.
-
Interim Report 2 2021/22
Strong sales growth for the 3rd consecutive quarter. Recent advancements in regenerative medicine create additional growth potential in clinical applications for the company.